Skip to main content

Table 4 Chemosensitivity testing in 50 soft tissue sarcoma patients

From: Feasibility of chemosensitivity testing in soft tissue sarcomas

Cytotoxics Resistant Low Sensitivity Moderate Sensitivity High Sensitivity Mean Sensitivity Index*
Actinomycin D 00/50 (00%) 10/50 (20%) 03/50 (06%) 37/50 (74%) 137
Doxorubicin (Adriamycin) 03/50 (06%) 02/50 (04%) 10/50 (20%) 35/50 (70%) 140
Ifosfamide 10/50 (32%) 00/50 (00%) 02/50 (04%) 32/50 (64%) 234
Epirubicin 08/50 (16%) 00/50 (00%) 12/50 (24%) 30/50 (60%) 245
Cisplatin 39/50 (82%) 11/50 (22%) 00/50 (00%) 00/50 (00%) 444
Dacarbazine 45/50 (95%) 05/50 (5%) 00/50 (00%) 00/50 (00%) 532
Vincristine 42/50 (84%) 08/50 (16%) 00/50 (00%) 00/50 (00%) 513
Doxorucicin + Ifosfamide 03/50 (06%) 00/50 (00%) 11/50 (22%) 36/50 (72%) 139
Actinomycin D + Ifosfamide 01/50 (2%) 08/50 (16%) 03/50 (06%) 38/50 (76%) 163
VAC** 03/50 (06%) 05/50 (10%) 07/50 (14%) 35/50 (70%) 218
CYVADIC*** 02/50 (04%) 00/50 (00%) 15/50 (30%) 33/50 (66%) 255
  1. *Data are means from individual chemosensitivity indices for each test drug or drug combination, which were calculated by summing up the tumor growth inhibition for each drug concentration tested followed by the subtraction of 600. A sensitivity index of 600 indicates unrestrained tumor cell growth and minimal drug sensitivity, whereas a sensitivity index of 0 reflects complete tumor growth inhibition and maximal drug sensitivity.
  2. **VAC: Vincristine, Actinomycin D, Cyclophosphamide
  3. ***CYVADIC: Cyclophosphamide, Vincristine, Doxorubicin, Dacarbazine